1. Home
  2. BNTC vs GDEV Comparison

BNTC vs GDEV Comparison

Compare BNTC & GDEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNTC
  • GDEV
  • Stock Information
  • Founded
  • BNTC 1995
  • GDEV 2009
  • Country
  • BNTC United States
  • GDEV Cyprus
  • Employees
  • BNTC N/A
  • GDEV N/A
  • Industry
  • BNTC Biotechnology: Pharmaceutical Preparations
  • GDEV EDP Services
  • Sector
  • BNTC Health Care
  • GDEV Technology
  • Exchange
  • BNTC Nasdaq
  • GDEV Nasdaq
  • Market Cap
  • BNTC 352.5M
  • GDEV N/A
  • IPO Year
  • BNTC N/A
  • GDEV N/A
  • Fundamental
  • Price
  • BNTC $13.74
  • GDEV $15.45
  • Analyst Decision
  • BNTC Strong Buy
  • GDEV Buy
  • Analyst Count
  • BNTC 7
  • GDEV 2
  • Target Price
  • BNTC $24.71
  • GDEV $70.00
  • AVG Volume (30 Days)
  • BNTC 37.1K
  • GDEV 37.4K
  • Earning Date
  • BNTC 05-16-2025
  • GDEV 05-27-2025
  • Dividend Yield
  • BNTC N/A
  • GDEV N/A
  • EPS Growth
  • BNTC N/A
  • GDEV N/A
  • EPS
  • BNTC N/A
  • GDEV 1.38
  • Revenue
  • BNTC N/A
  • GDEV $420,933,000.00
  • Revenue This Year
  • BNTC N/A
  • GDEV $4.73
  • Revenue Next Year
  • BNTC N/A
  • GDEV $16.15
  • P/E Ratio
  • BNTC N/A
  • GDEV $11.17
  • Revenue Growth
  • BNTC N/A
  • GDEV N/A
  • 52 Week Low
  • BNTC $5.74
  • GDEV $8.60
  • 52 Week High
  • BNTC $16.90
  • GDEV $42.76
  • Technical
  • Relative Strength Index (RSI)
  • BNTC 51.06
  • GDEV 62.08
  • Support Level
  • BNTC $13.10
  • GDEV $10.25
  • Resistance Level
  • BNTC $15.69
  • GDEV $18.33
  • Average True Range (ATR)
  • BNTC 0.73
  • GDEV 1.43
  • MACD
  • BNTC -0.01
  • GDEV 0.79
  • Stochastic Oscillator
  • BNTC 24.71
  • GDEV 64.36

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Share on Social Networks: